Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose
levels in both fasting and postprandial states and preserves pancreatic beta cell function in
patients with type 2 diabetes. Their mechanism of action is derived from increased incretin
(GLP-1) levels, which stimulate insulin secretion as well as insulin biosynthesis and inhibit
glucagon secretion from pancreas. Recent studies reported that combination therapy with
DPP-IV inhibitors and metformin have additive or synergistic effects in lowering glycose
level, preserving beta-cell mass and function as well as enhancing insulin sensitivity.
However, there have been few studies about the difference of glucose lowering effect of
combination therapy of DPP-IV inhibitors and metformin according to the secretory capacity of
pancreas.
The researchers hypothesized that combination therapy with DPP-IV inhibitor and metformin may
have more favorable glucose lowering effect in type 2 diabetic patients who have preserved
pancreatic secretory function. The researchers plan to investigate the difference of glucose
lowering effect of 24 weeks treatment with sitagliptin (DPP-IV inhibitor) in combination with
metformin according to basal c-peptide and glucagon level in type 2 diabetic patients.